Pulse Biosciences Schedules Fourth Quarter & Full Year 2025 Financial Results Conference Call for February 19, 2026
News > Business News
Audio By Carbonatix
4:05 PM on Wednesday, February 4
The Associated Press
HAYWARD, Calif.--(BUSINESS WIRE)--Feb 4, 2026--
Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced it will report business updates and financial results for the fourth quarter and full year 2025 after market close on Thursday, February 19, 2026.
Company management will host a corresponding conference call beginning at 1:30pm PT / 4:30pm ET. Investors interested in listening to the conference call may do so by dialing 1-800-715-9871 from the U.S. or 1-646-307-1963 internationally and providing Conference ID 7647402. A live and recorded webcast of the event will be available on the Pulse Biosciences Investors website at http://investors.pulsebiosciences.com/.
About Pulse Biosciences®
Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the intention as well as the potential to improve the quality of life for patients. The Company’s proprietary nPulse™ technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. The Company is actively pursuing the development of its nPulse technology for use in the treatment of atrial fibrillation and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers, such as surgical soft tissue ablation.
Pulse Biosciences, nPulse, Vybrance, CellFX, Nano-Pulse Stimulation, NPS, nsPFA, CellFX nsPFA, nanosecond PFA and the stylized logos are among the trademarks and/or registered trademarks of Pulse Biosciences, Inc. in the United States and other countries.
View source version on businesswire.com:https://www.businesswire.com/news/home/20260204165656/en/
CONTACT: Investors:
Pulse Biosciences, Inc.
Jon Skinner, CFO
[email protected] Group
Philip Trip Taylor
415.937.5406
KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA
INDUSTRY KEYWORD: RESEARCH MEDICAL DEVICES CLINICAL TRIALS STEM CELLS BIOTECHNOLOGY HEALTH PHARMACEUTICAL GENERAL HEALTH SCIENCE
SOURCE: Pulse Biosciences, Inc.
Copyright Business Wire 2026.
PUB: 02/04/2026 04:05 PM/DISC: 02/04/2026 04:05 PM
http://www.businesswire.com/news/home/20260204165656/en
